Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two common autoimmune rheumatic diseases that vary in severity, clinical presentation, and disease course between individuals. Molecular and genetic studies of both diseases have identified candidate genes and molecular pathways that are linked to various disease outcomes and treatment responses. Currently, patients can be grouped into molecular subsets in each disease, and these molecular categories should enable precision medicine approaches to be applied in rheumatic diseases. In this article, we will review key lessons learned about disease heterogeneity and molecular characterization in rheumatology, which we hope will lead to personalized therapeutic strategies.
TheofilopoulosANKonoDHBaccalaR.The multiple pathways to autoimmunity. Nat Immunol2017; 18(7): 716–724.
2.
CooperGSBynumMLSomersEC.Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun2009; 33(3–4): 197–207.
3.
GoulielmosGNZervouMIVazgiourakisVM, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene668: 59–72.
4.
SinicatoNAPostalMAppenzellerS, et al. Defining biological subsets in systemic lupus erythematosus: Progress toward personalized therapy. Pharmaceut Med31: 81–88.
5.
LangefeldCDAinsworthHCCunninghame GrahamDS, et al. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun2017; 8: 16021.
6.
GabrielSE.The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am2001; 27(2): 269–281.
7.
NiewoldTBHarrisonMJPagetSA.Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM2007; 100(4): 193–201.
8.
KrootEJde JongBAvan LeeuwenMA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum2000; 43(8): 1831–1835.
9.
PadyukovLSeielstadMOngRT, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis2011; 70(2): 259–265.
10.
IwamotoTNiewoldTB.Genetics of human lupus nephritis. Clinical Immunology2017; 185: 32–39.
11.
SanchezENadigARichardsonBC, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis2011; 70(10): 1752–1757.
12.
FernandezMAlarconGSCalvo-AlenJ, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum2007; 57(4): 576–584.
13.
BastianHMRosemanJMMcGwinG, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk Factors for Lupus Nephritis after Diagnosis. Lupus2002; 11(3): 152–160.
14.
MokCCLauCS.Lupus in Hong Kong Chinese. Lupus2003; 12(9): 717–722.
15.
LewisMJJawadAS.The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology2017; 56: i67–i77.
16.
NiewoldTB.Advances in lupus genetics. Curr Opin Rheumatol2015; 27(5): 440–447.
17.
FreedmanBILangefeldCDAndringaKK, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol2014; 66(2): 390–396.
18.
IsenbergDAppelGBContrerasG, et al. Influence of race/ethnicity on response to lupus nephritis treatment: The ALMS study. Rheumatology2010; 49(1): 128–140.
19.
SinicatoNAde OliveiraLLapaAT, et al. Familial aggregation of childhood and adulthood-onset systemic lupus erythematosus. Arthritis Care Res Epub ahead of print25May2019. DOI: 10.1002/acr.23931.
20.
AlmlofJCNystedtSLeonardD, et al. Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. Hum Genet2019; 138(2): 141–150.
21.
Wampler MuskardinTLNiewoldTB. Type I interferon in rheumatic diseases. Nature Rev Rheumatol2018; 14(4): 214–228.
22.
WeckerleCEFranekBSKellyJA, et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum2011; 63(4): 1044–1053.
23.
KariukiSNGhodke-PuranikYDorschnerJM, et al. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun2015; 16(1): 15–23.
24.
Ghodke-PuranikYImgruetMDorschnerJM, et al. Novel genetic associations with interferon in systemic lupus erythematosus identified by replication and fine-mapping of trait-stratified genome-wide screen. Cytokine. Epub ahead of print 23 January 2019. DOI: 10.1016/j.cyto.2018.12.014.
25.
OkeVGunnarssonIDorschnerJ, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther2019; 21(1): 107.
26.
RitterhouseLLCroweSRNiewoldTB, et al. B lymphocyte stimulator levels in systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum2011; 63(12): 3931–3941.
27.
NiewoldTB.Connective tissue diseases: Targeting type I interferon in systemic lupus erythematosus. Nat Rev Rheumatol2016; 12(7): 377–378.
FengXRederNPYanamandalaM, et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci2012; 313(1–2): 48–53.
30.
FengXHanDKilaruBK, et al. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol2012; 69(10): 1303–1309.
31.
VossenaarERZendmanAJvanVenrooijWJ, et al. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays2003; 25(11): 1106–1118.
32.
FurukawaHOkaSShimadaK, et al. Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis. J Hum Genet2015; 60(11): 691–696.
33.
HedstromAKRönnelidJKlareskogL, et al. Smoking, HLA-genes and serology in rheumatoid arthritis; complex relationships investigated in the Swedish EIRA case-control study. Arthritis Rheumatol2019; 71: 1504–1511.
34.
GwinnuttJMSymmonsDPMMac GregorAJ, et al. Twenty-year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis results from the Norfolk Arthritis Register. Arthritis Rheumatol2017; 69(8): 1566–1575.
35.
BoersM.Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum2003; 48(7): 1771–1774.
36.
SmolenJSEmeryPFerraccioliGF, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: The CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis2015; 74(5): 843–850.
37.
KlaasenRWijbrandtsCAGerlagDM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum2011; 63(2): 359–364.
38.
HyrichKLWatsonKDSilmanAJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: Results from the British society for rheumatology biologics register. Rheumatology2006; 45(12): 1558–1565.
39.
PotterCHyrichKLTraceyA, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis2009; 68(1): 69–74.
40.
HiggsBWLiuZWhiteB, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis2011; 70(11): 2029–2036.
41.
RatermanHGVosslamberSdeRidderS, et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther2012; 14(2): R95.
42.
WrightHLThomasHBMootsRJ, et al. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology2015; 54(1): 188–193.
43.
Wampler MuskardinTVashishtPDorschnerJM, et al. Increased pretreatment serum IFN-beta/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis. Ann Rheum Dis2016; 75(10): 1757–1762.
44.
ZhangFWeiKSlowikowskiK, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol2019; 20(7): 928–942.
45.
OrangeDEAgiusPDi CarloEF, et al. Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data. Arthritis Rheumatol2018; 70(5): 690–701.
46.
DennisGJrHolwegCTKummerfeldSK, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther2014; 16(2): R90.
